Agency / Source: GenScript Corporation

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GenScript Launches Guaranteed Gene-to-Protein Service Package Following the Technology Breakthrough from OptimumGene™ Gene Optimization - Internationally recognized biology contract research organization, GenScript USA Inc. launched Gene-to-Protein custom service package guaranteeing at least 10 mg of purified protein
GenScript Launches Guaranteed Gene-to-Protein Service Package Following the Technology Breakthrough from OptimumGene™ Gene Optimization

 

PRZOOM - /newswire/ - Piscataway, NJ, United States, 2009/10/16 - Internationally recognized biology contract research organization, GenScript USA Inc. launched Gene-to-Protein custom service package guaranteeing at least 10 mg of purified protein. 1548:HK

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

GenScript USA Inc. has recently launched Gene-to-Protein custom service package guaranteeing at least 10 mg of purified protein after its recent OptimumGene™ codon optimization technology breakthrough.

The breakthrough in GenScript’s OptimumGene™ codon optimization technology can typically increase protein expression level in E. coli by a minimum of 10-fold. A variety of parameters critical to transcription efficiency, translation efficiency and protein folding are optimized. The recently launched Gene-to-Protein package implements this adapted technology and guarantees 10 mg of purified protein in delivery. “All testing results for this new package have been satisfying over the past several months. Once launched, it can give our clients the best guarantee in the industry.” commented by Dr. Timothy Xia, Director of GenScript’s Protein Department.

With a fast turn-around time, the Gene-to-Protein package enables research clients to receive target proteins starting by merely inputting digital gene sequences. Using the advanced proprietary algorithm, the OptimumGene™ Gene Design technology will be implemented at the beginning of the protocol, which includes gene synthesis, subcloning, expression optimization, and protein purification.

GenScript (genscript.com) is a contract research organization (CRO) specialized in biological research and drug discovery services. Its service portfolio includes bio-reagent services, assay development & screening, lead optimization, and antibody drug development. The renowned one-stop bioreagent services include custom gene synthesis and molecular biology, custom protein expression and purification, custom peptide synthesis, antibody production, and custom cell line development. Headquartered in Piscataway, New Jersey, GenScript has become a world-leading Biology CRO and the largest gene synthesis supplier in the USA, with subsidiaries in France, Japan, and China.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: GenScript Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


GenScript Launches Guaranteed Gene-to-Protein Service Package Following the Technology Breakthrough from OptimumGene™ Gene Optimization

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
GenScript Press Room |
Contact: Sally Wang - GenScript.com 
732-885-9188 info[.]genscript.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GenScript Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From GenScript Corporation / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Ono Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment
Ono Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory
SCHOTT Pharma Launches EVERIC® Lyo & Amber Vials for Light-sensitive ADCs
Arbitration Tribunal Upholds Ipsen’s Termination of R&D Agreement with Galderma
New Data Reinforces Ipsen’s Commitment to Bringing Solutions and Addressing Care Gaps in Neurological Diseases At TOXINS
Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients
U.S. FDA Grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in First Line Unfit Acute Myeloid Leukemia
Additional Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer in South Korea
BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  BizJobs.com

Visit  RightITnow, Inc.

Visit  Limelon Advertising, Co.







 
  ©2005-2026 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today